This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
WHO. Global tuberculosis report 2022. 2022. Available from: https://www.who.int/publications/i/item/9789240061729. Accessed June 20, 2022.Search in Google Scholar
Sharma SK, Mohan A, Kohli M. Extrapulmonary tuberculosis. Expert Review of Respiratory Medicine. 2021;15(7): 931–948. doi:10.1080/17476348.2021.1927718.Search in Google Scholar
Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberculosis and Respiratory Diseases (Seoul). 2015;78(2): 47–55. doi:10.4046/trd.2015.78.2.47.Search in Google Scholar
Prakash AK, Datta B, Goyal P, Chatterjee P, Gupta G. GENEXPERT gives early diagnosis in early tuberculosis. European Respiratory Journal. 2016;48: A2775. doi:10.1183/13993003. congress-2016.PA2775.Search in Google Scholar
Balbi GGM, Machado-Ribeiro F, Marques CDL, Signorelli F, Levy RA. The interplay between tuberculosis and systemic lupus erythematosus. Current Opinion in Rheumatology. 2018;30(4): 395–402. doi:10.1097/BOR.0000000000000493.Search in Google Scholar
Dunn RN, Ben Husien M. Spinal tuberculosis: review of current management. The Bone & Joint Journal. 2018;100-B(4): 425–431. doi:10.1302/0301-620X.100B4.BJJ-2017-1040.R1.Search in Google Scholar
Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;27(11): 1819–1827. doi:10.1177/0961203318792352.Search in Google Scholar
WHO. WHO Guidelines for treatment of tuberculosis. WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240048126. Accessed June 20, 2022.Search in Google Scholar
Dobler CC. 2016. Biologic agents and tuberculosis. Microbiol Spectrum 4(6):TNMI7-0026-2016. doi:10.1128/microbiolspec. TNMI7-0026-2016.Search in Google Scholar
Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheuma. 2009;60(7): 1884–1894. doi:10.1002/art.24632.Search in Google Scholar
Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61(9): 791–794. doi:10.1136/thx.2006.058867.Search in Google Scholar
Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infection Control & Hospital Epidemiology. 2005;26(3): 273–280. doi:10.1086/502539.Search in Google Scholar
Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulmonary Medicine. 2013;2013: ArticleID828939,11 pages. doi:10.1155/2013/828939.Search in Google Scholar
Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infectious Diseases. 2017;17: 231. doi:10.1186/s12879-017-2330-z.Search in Google Scholar
Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection— associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases. 2010;50(Suppl_3): S201–S207. doi:10.1086/651492.Search in Google Scholar
